Zolbetuximab

MCE 國際站：Zolbetuximab

CAS：1496553-00-4

品牌：MedChemExpress (MCE)

存儲條件：Please store the product under the recommended conditions in the Certificate of Analysis.

生物活性： Zolbetuximab (IMAB362) 是一種靶向Claudin-18.2 的單克隆抗體。 Zolbetuximab 通過免疫效應機制介導 Claudin-18.2 陽性細胞的特異性殺傷。 Zolbetuximab可用于胃腸道腺癌和胰腺腫瘤的研究^[1]。

體外：Zolbetuximab (0-100 μg/mL) 與 CLDN18.2+ PC 細胞結合，誘導抗體依賴性細胞毒性 (ADCC) 和補體依賴性細胞毒性 (CDC)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內：單獨使用 Zolbetuximab (200 μg，靜脈注射) 以及與 Gemcitabine (HY-17026) (50 mg/kg，腹腔注射) 聯合使用，在小鼠 BxPC-3-CLDN18.2 異種移植模型中表現出抗腫瘤活性[2]。 Zolbetuximab (5.7 mg/kg，腹腔注射，每周 3 次，持續五周) 抑制 SNU-620 細胞異種移植模型中的腫瘤生長[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] Dosage: 200 μg alone or with 50 mg/kg Gemcitabine Administration: i.v.; i.p. (Gemcitabine) Result: Inhibited tumor growth in two models, and prevented lung metastasis formation. Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. Clinical Trial

熱賣產品：NMS-P715  | Aderbasib  | ZD-4190  | Donepezil  | Muscone  | WM-1119  | Glycochenodeoxycholic acid (sodium salt)  | CL075  | Ligustroflavone  | Envafolimab

研究領域：Others

作用靶點：Others

熱門產品線：重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

參考文獻：

[1]. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.[2]. Türeci ?, et al. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2018 Nov 10;8(1):e1523096. [3]. Zhong W, et al. Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers. Front Immunol. 2022 Jun 28;13:885424.